Guo-Shiou Liao1, Yu-Ching Chou2, Huan-Ming Hsu1, Ming-Shen Dai3, Jyh-Cherng Yu4. 1. Division of General Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan. 2. School of Public Health, National Defense Medical Center, Taipei, Taiwan. 3. Division of Hematology/Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan. 4. Division of General Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan. Electronic address: doc20106@ndmctsgh.edu.tw.
Abstract
BACKGROUND: Breast cancer subtypes (BCSs) are predictive of responses to specific therapies and of prognostic value for clinical outcomes. This study aimed to evaluate the relative 5-year overall survival (OS) and recurrence-free survival rates (RFS) based on lymph node (LN) status among BCSs. METHODS: Medical records of 1,399 breast cancer patients treated from 2006 to 2011 were retrospectively reviewed. Pathologic findings, type of treatment, and OS and RFS were evaluated for 5 molecular subtypes. RESULTS: Luminal A cancers accounted for 40.9% of the total, luminal B 21.5%, luminal human epidermal growth factor receptor 2 (HER2) 24.8%, HER2 6.9%, and triple negative 5.9%, of which 30% (n = 395) were LN positive. Analysis of patient characteristics showed significant differences among BCSs in age, tumor size, LN status, chemotherapy, and endocrine therapy. Adjustments for age and tumor size revealed significant differences in OS according to the nodal status in luminal A, luminal B, and luminal HER2 subtypes, and with RFS in the luminal B and luminal HER2 subtypes. CONCLUSION: LN status in BCS presents an important prognostic factor of OS and RFS.
BACKGROUND:Breast cancer subtypes (BCSs) are predictive of responses to specific therapies and of prognostic value for clinical outcomes. This study aimed to evaluate the relative 5-year overall survival (OS) and recurrence-free survival rates (RFS) based on lymph node (LN) status among BCSs. METHODS: Medical records of 1,399 breast cancerpatients treated from 2006 to 2011 were retrospectively reviewed. Pathologic findings, type of treatment, and OS and RFS were evaluated for 5 molecular subtypes. RESULTS: Luminal A cancers accounted for 40.9% of the total, luminal B 21.5%, luminal humanepidermal growth factor receptor 2 (HER2) 24.8%, HER2 6.9%, and triple negative 5.9%, of which 30% (n = 395) were LN positive. Analysis of patient characteristics showed significant differences among BCSs in age, tumor size, LN status, chemotherapy, and endocrine therapy. Adjustments for age and tumor size revealed significant differences in OS according to the nodal status in luminal A, luminal B, and luminal HER2 subtypes, and with RFS in the luminal B and luminal HER2 subtypes. CONCLUSION: LN status in BCS presents an important prognostic factor of OS and RFS.
Authors: Irianiwati Widodo; Ery Kus Dwianingsih; Sumadi Lukman Anwar; Triningsih Fx Ediati; Totok Utoro; Teguh Aryandono Journal: Asian Pac J Cancer Prev Date: 2017-05-01
Authors: Fereshteh Ghafari; Mohammad Reza Rajabi; Tahereh Mazoochi; Mohsen Taghizadeh; Hossein Nikzad; Mohammad Ali Atlasi; Aliakbar Taherian Journal: Asian Pac J Cancer Prev Date: 2017-03-01
Authors: Shelly Wen; Lucy Manuel; Moira Doolan; Justin Westhuyzen; Thomas P Shakespeare; Noel J Aherne Journal: Breast Cancer (Dove Med Press) Date: 2020-03-06